SCL Science

SCL사이언스 · 246960

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$46.2M (₩63.7B)

Overview

SCL Science makes medical devices that stop bleeding during surgical and vascular procedures, its flagship product, InnoSEAL, is a hemostatic pad that bonds with blood proteins to control bleeding.

Hospitals and clinicians performing vascular interventions and abdominal surgeries are the primary users of its devices. Listed on KOSDAQ, Korea's tech and small-cap board, the company also runs two other business lines: a temperature-controlled logistics service for biological and pharmaceutical shipments, and a data-platform business offering AI-assisted medical-imaging and health-screening software.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$15.9M
▲ +364.6% YoY
Operating profit · FY2025
−US$2.5M
Loss narrowed
Net income · FY2025
−US$3M
Loss widened

Revenue

  • FY2023US$958K
  • FY2024US$3.4M
  • FY2025US$15.9M

Operating profit

  • FY2023−US$2.9M
  • FY2024−US$2.7M
  • FY2025−US$2.5M

Net income

  • FY2023−US$3.6M
  • FY2024−US$2.7M
  • FY2025−US$3M

Key ratios (FY2025)

ROE
-17.5%
Debt/Eq
240.1%
Op. margin
-15.4%
Net margin
-18.7%
Rev. YoY
▲ +364.6%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.